3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
145
Lymphoma
104
Lymphoma, Large B-Cell, Diffuse
76
Sarcoma
62
Hodgkin Disease
46
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Burkitt Lymphoma
35
Triple Negative Breast Neoplasms
31
Lymphoma, Non-Hodgkin
29
Lymphoma, Mantle-Cell
27
Leukemia
25
Neoplasms
22
Lymphoma, Follicular
22
Neoplasm Metastasis
21
Multiple Myeloma
21
Neuroblastoma
20
Carcinoma, Hepatocellular
18
Ovarian Neoplasms
16
Lymphoma, B-Cell
16
Liver Neoplasms
14
Urinary Bladder Neoplasms
12
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
12
Osteosarcoma
12
Lymphoma, T-Cell, Peripheral
11
Lymphoma, Large-Cell, Anaplastic
11
Inflammatory Breast Neoplasms
11
Breast Neoplasms, Male
11
Prostatic Neoplasms
10
Dendritic Cell Sarcoma, Interdigitating
10
Lymphoma, Large-Cell, Immunoblastic
9
Interventions
Cyclophosphamide
10
ofatumumab
8
fludarabine
6
Rituximab
5
fludarabine phosphate
4
Bendamustine Hydrochloride
4
venetoclax
3
obinutuzumab
3
ibrutinib
3
acalabrutinib
3
Melphalan
3
pirtobrutinib
2
Whole-Body Irradiation
2
Vincristine
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Lenalidomide
2
Immunotherapy, Adoptive
2
Busulfan
2
Bortezomib
2
Alemtuzumab
2
zanubrutinib
1
thymoglobulin
1
tenofovir alafenamide
1
pomalidomide
1
pivalyloxymethyl butyrate
1
pegaspargase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia, B-Cell
×
Doxorubicin
×
Clear all
NCT03899337
2023-01-09
STELLAR
University of Birmingham
Phase 2
Recruiting
105 enrolled